Antibody-Drug Conjugates (ADC) Technology Research and Global Markets Report 2024-2025 & 2029 with Profiles of Leading Players - F. Hoffmann-La Roche.

Market Overview - The global sales of antibody-drug conjugates (ADCs) are experiencing rapid growth, with growth rates of 36.5% in 2022 and 40.7% in 2023, reaching a market value of $10.8 billion in 2023 [2] - The ADC market is projected to exceed $47 billion by the end of 2029, with a compound annual growth rate (CAGR) of 28.4% during the forecast period [2][10] - Fourteen ADCs have been introduced to the global market, with thirteen currently available [2] Market Dynamics - The ADC market is driven by technological advancements, an increasing number of cancer patients, and a growing demand for biologics in cancer treatment [4] - Increased funding and investments in the ADC market indicate strong market sentiment regarding the potential of ADCs to meet unmet medical needs [5] - The clinical pipeline for ADCs is expanding, which is a significant factor in market growth [5] Market Segmentation - The microtubule inhibitors market for ADCs is expected to grow from $6.7 billion in 2023 to $25.7 billion by 2029, with a CAGR of 25.6% from 2024 to 2029 [6] - The DNA targeting agents market for ADCs is projected to increase from $4.1 billion in 2023 to $21.1 billion by 2029, with a CAGR of 32.2% from 2024 to 2029 [6] Report Scope and Content - The report includes 25 data tables and 45 additional tables, providing an updated review of the global ADC market, market trends from 2021-2023, and forecasts for 2024-2029 [8] - It covers market share analysis by payload type, linker type, antibody type, indication, and region, along with discussions on the latest approvals, clinical trials, and market dynamics [8][11] - Major companies profiled in the report include AbbVie Inc., ADC Therapeutics SA, Daiichi Sankyo Co. Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., and Pfizer Inc. [9]